Moreover, our work expands the spectrum of reported fusions involving NRG1 and novel partner genes, ultimately considering the utility of ERBB/ERBB2/ERBB3-directed anti-cancer agents, such as afitinib, tarloxotinib, seribantumab, zenocutuzumab, and others, that are under investigation for the treatment of NRG1 fusion-positive tumors (8–10). Here, ERBB3 is linked to cancer.